166 related articles for article (PubMed ID: 2979764)
1. In vivo characterization of P388 leukemia resistant to mitomycin C.
Rose WC; Huftalen JB; Bradner WT; Schurig JE
In Vivo; 1987; 1(1):47-52. PubMed ID: 2979764
[TBL] [Abstract][Full Text] [Related]
2. [The cross resistance to cytostatics of leukemia P388 cells with induced resistance to doxorubicin].
Donenko FV; Sitdikova SM; Kabieva AO
Biull Eksp Biol Med; 1993 Sep; 116(9):309-11. PubMed ID: 8118011
[TBL] [Abstract][Full Text] [Related]
3. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
Yang JM; Goldenberg S; Gottesman MM; Hait WN
Cancer Res; 1994 Feb; 54(3):730-7. PubMed ID: 7905786
[TBL] [Abstract][Full Text] [Related]
5. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
Johnson RK; Chitnis MP; Embrey WM; Gregory EB
Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
7. [Cross-resistance of HO-221 and various antitumor agents in sublines of mouse leukemia].
Nakajima T; Masuda H; Okamoto T; Watanabe M; Yokoyama K; Yamada N; Fujimoto S; Tsukagoshi S; Taguchi T
Gan To Kagaku Ryoho; 1991 Feb; 18(2):201-9. PubMed ID: 1899547
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
Chandrasekaran B; Dimling J; Capizzi RL
Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
10. Overcoming drug resistance in cancer cells with synthetic isoprenoids.
Yamaguchi T; Nakagawa M; Shiraishi N; Yoshida T; Kiyosue T; Arita M; Akiyama S; Kuwano M
J Natl Cancer Inst; 1986 May; 76(5):947-53. PubMed ID: 3457980
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.
Bradner WT; Rose WC; Schurig JE; Schlein A; Huftalen JB
Cancer Res; 1984 Dec; 44(12 Pt 1):5619-23. PubMed ID: 6437670
[TBL] [Abstract][Full Text] [Related]
12. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
Lepri E; Menconi E; Barzi AM
Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
[TBL] [Abstract][Full Text] [Related]
13. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.
Ramu A; Fuks Z; Gatt S; Glaubiger D
Cancer Res; 1984 Jan; 44(1):144-8. PubMed ID: 6690032
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
15. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52.
Shinoda H; Inaba M; Tsuruo T
Cancer Res; 1989 Apr; 49(7):1722-6. PubMed ID: 2924316
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance of cultured murine leukemia vincristine-resistant P388 cells to vinblastine, vindesine, and bis (N-ethylidene vindesine) disulfide, disulfate.
Wilkoff LJ; Dulmadge EA
J Natl Cancer Inst; 1982 Jun; 68(6):1023-6. PubMed ID: 6953266
[TBL] [Abstract][Full Text] [Related]
17. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers.
Tsuruo T; Iida H; Nojiri M; Tsukagoshi S; Sakurai Y
Cancer Res; 1983 Jun; 43(6):2905-10. PubMed ID: 6850602
[TBL] [Abstract][Full Text] [Related]
18. Nitrotriazole AK-2123 enhances mitomycin C activity in mice bearing multidrug-resistant tumors.
Goncharova SA; Rajewskaya TA; Konovalova NP; Kagiya TV
J Chemother; 2001 Dec; 13(6):635-40. PubMed ID: 11806625
[TBL] [Abstract][Full Text] [Related]
19. Effects of BMY 25282, a mitomycin C analogue, in mitomycin C-resistant human colon cancer cells.
Willson JK; Long BH; Chakrabarty S; Brattain DE; Brattain MG
Cancer Res; 1985 Nov; 45(11 Pt 1):5281-6. PubMed ID: 3931904
[TBL] [Abstract][Full Text] [Related]
20. [The radiosensitizer AK-2123 enhances sensitivity of MDR-tumors to Mitomycin C].
Goncharova SA; Raevskaia TA; Konovalova NP; Kagiia VT
Vopr Onkol; 2000; 46(2):202-8. PubMed ID: 10853422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]